Nicox S.A.
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-11-07 07:30 |
Nicox : Plans de développement et de partenariat pour le NCX 470 dans le glauco…
|
French | 455.6 KB | ||
| 2022-11-02 17:45 |
NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE AU 3…
|
French | 189.0 KB | ||
| 2022-11-02 17:45 |
Publication of the Number of Shares Composing the Share Capital and of the Tota…
|
English | 190.1 KB | ||
| 2022-10-31 07:30 |
Nicox : NCX 470 atteint l’objectif primaire de l’étude Mont Blanc, la première …
|
French | 449.6 KB | ||
| 2022-10-31 07:30 |
Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glau…
|
English | 352.6 KB | ||
| 2022-10-19 07:30 |
Nicox : Résumé financier et point d’activité du troisième trimestre 2022
|
French | 452.0 KB | ||
| 2022-10-19 07:30 |
Nicox Provides Third Quarter 2022 Financial and Business Highlights
|
English | 433.4 KB | ||
| 2022-10-03 17:45 |
Nombre de droits de vote au 30 septembre 2022
|
French | 189.0 KB | ||
| 2022-10-03 17:45 |
Number of voting rights as of September 30, 2022
|
English | 189.9 KB | ||
| 2022-09-30 07:30 |
Nicox confirme son éligibilité au PEA-PME
|
French | 319.4 KB | ||
| 2022-09-19 07:30 |
Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blan…
|
English | 338.1 KB | ||
| 2022-09-19 07:30 |
Nicox : Visite finale des derniers patients de l’étude de phase 3 Mont Blanc su…
|
French | 341.9 KB | ||
| 2022-09-16 07:30 |
Nicox : Point des activités et résultats financiers du premier semestre 2022
|
French | 610.9 KB | ||
| 2022-09-16 07:30 |
Nicox Provides First Half 2022 Business Update and Financial Results
|
English | 506.6 KB | ||
| 2022-09-15 17:45 |
Nicox : Rapport semestriel 2022
|
French | 112.5 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nicox S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
